JP2021533084A5 - - Google Patents
Info
- Publication number
- JP2021533084A5 JP2021533084A5 JP2020570163A JP2020570163A JP2021533084A5 JP 2021533084 A5 JP2021533084 A5 JP 2021533084A5 JP 2020570163 A JP2020570163 A JP 2020570163A JP 2020570163 A JP2020570163 A JP 2020570163A JP 2021533084 A5 JP2021533084 A5 JP 2021533084A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- lif
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023187689A JP7603772B2 (ja) | 2018-06-18 | 2023-11-01 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18382432.5 | 2018-06-18 | ||
| EP18382432 | 2018-06-18 | ||
| PCT/IB2019/000812 WO2019243900A2 (en) | 2018-06-18 | 2019-06-17 | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023187689A Division JP7603772B2 (ja) | 2018-06-18 | 2023-11-01 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533084A JP2021533084A (ja) | 2021-12-02 |
| JP2021533084A5 true JP2021533084A5 (enExample) | 2022-06-24 |
| JP7379390B2 JP7379390B2 (ja) | 2023-11-14 |
Family
ID=62837845
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020570163A Active JP7379390B2 (ja) | 2018-06-18 | 2019-06-17 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
| JP2023187689A Active JP7603772B2 (ja) | 2018-06-18 | 2023-11-01 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023187689A Active JP7603772B2 (ja) | 2018-06-18 | 2023-11-01 | 癌の治療に使用するためのｌｉｆ阻害剤と白金系抗悪性腫瘍剤の組み合わせ |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210187106A1 (enExample) |
| EP (1) | EP3806899A2 (enExample) |
| JP (2) | JP7379390B2 (enExample) |
| KR (1) | KR20210022065A (enExample) |
| CN (1) | CN112955178B (enExample) |
| AU (2) | AU2019291307B2 (enExample) |
| CA (1) | CA3103369A1 (enExample) |
| EA (1) | EA202092964A1 (enExample) |
| IL (1) | IL279444A (enExample) |
| MA (1) | MA52300A (enExample) |
| SG (1) | SG11202012576QA (enExample) |
| WO (1) | WO2019243900A2 (enExample) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| AU4231393A (en) * | 1992-05-08 | 1993-12-13 | Genentech Inc. | Antibodies to leukemia inhibitory factor |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| ES2363358B1 (es) * | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
| EP2371860A1 (en) * | 2010-04-05 | 2011-10-05 | Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron | Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation |
| WO2016040657A1 (en) * | 2014-09-10 | 2016-03-17 | The Regents Of The University Of California | TARGETING K-RAS-MEDIATED SIGNALING PATHWAYS AND MALIGNANCY BY ANTI-hLIF ANTIBODIES |
| EP3283886B1 (en) * | 2015-04-17 | 2020-01-15 | Eisai Inc. | Methods for treating lung cancer |
| US10583191B2 (en) * | 2016-12-19 | 2020-03-10 | Mosaic Biomedicals Slu | Antibodies against LIF and uses thereof |
| KR20210008514A (ko) * | 2018-05-14 | 2021-01-22 | 메디뮨 리미티드 | Lif에 대한 항체 및 이의 투여 형태 |
-
2019
- 2019-06-17 AU AU2019291307A patent/AU2019291307B2/en not_active Ceased
- 2019-06-17 CN CN201980053679.1A patent/CN112955178B/zh active Active
- 2019-06-17 MA MA052300A patent/MA52300A/fr unknown
- 2019-06-17 KR KR1020217001441A patent/KR20210022065A/ko not_active Ceased
- 2019-06-17 CA CA3103369A patent/CA3103369A1/en active Pending
- 2019-06-17 EP EP19782687.8A patent/EP3806899A2/en active Pending
- 2019-06-17 JP JP2020570163A patent/JP7379390B2/ja active Active
- 2019-06-17 SG SG11202012576QA patent/SG11202012576QA/en unknown
- 2019-06-17 US US17/252,449 patent/US20210187106A1/en not_active Abandoned
- 2019-06-17 EA EA202092964A patent/EA202092964A1/ru unknown
- 2019-06-17 WO PCT/IB2019/000812 patent/WO2019243900A2/en not_active Ceased
-
2020
- 2020-12-14 IL IL279444A patent/IL279444A/en unknown
-
2023
- 2023-11-01 JP JP2023187689A patent/JP7603772B2/ja active Active
-
2024
- 2024-07-01 AU AU2024204564A patent/AU2024204564A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111182919B (zh) | 抗cd137抗体 | |
| US9527913B2 (en) | Humanized pan-HER antibody compositions | |
| JP2019110906A5 (enExample) | ||
| RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2011111746A (ru) | Композиции рекомбинантных антител против рецептора эпидермального фактора роста | |
| HRP20180104T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih s her-3 | |
| JP2017149720A5 (enExample) | ||
| Liu et al. | Cell‐specific biomarkers and targeted biopharmaceuticals for breast cancer treatment | |
| RU2014138040A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| JP2018501197A5 (enExample) | ||
| RU2014138038A (ru) | Фармацевтическая композиция для лечения профилактики рака | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2018538274A5 (enExample) | ||
| JP2013510868A5 (enExample) | ||
| RU2014138041A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| HRP20170879T1 (hr) | Genetski proizvodi koji su diferencijalno izraženi u tumorima i njihova primjena | |
| JP2023518153A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| IL276675B1 (en) | Anti-pd-1 antibodies and uses thereof | |
| JP2021501567A5 (enExample) | ||
| JP2020522512A5 (enExample) | ||
| JP2021523906A5 (enExample) | ||
| JP2025148452A5 (enExample) | ||
| JPWO2022270524A5 (enExample) | ||
| JP2023519807A5 (enExample) |